The United States food and Drug Administration today announced it has added information on cardiovascular risk in the labelling of medicinal products for diabetes Avandia (rosiglitazone). The changes apply both to the medical patient labeling and medication guide.
In September 2010, the FDA announced that it would restrict the use of the drug to patients with diabetes type 2, who were unable to control their disease with other medications. The move came in response to data showing the drug posed an increased risk of cardiovascular events, including heart attack, in patients taking Avandia.
Thousands of lawsuits related to Avandia have been submitted in recent years. For more information on these and other defective drug demands relating to drugs, such as acts, Levaquin and Cipro, visit the pages of the your legal guide focusing on these drugs. Your Legal Guide also contains information on demands of death, those relating to the deaths included defective drugs.
This entry was posted on Thursday, February 03, 2011 at 3: 33 pm and is filed in Uncategorized. You can follow any responses to this entry through the RSS 2.0 source. Comments and pings are currently closed.
No hay comentarios:
Publicar un comentario